FDA Drug Recalls

Recalls / Class II

Class IID-0573-2025

Product

RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01

Affected lot / code info
Lot: TRB23802AC, Expires: 03/18/2026; TRA22804AA, Expires: 10/18/2025

Why it was recalled

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Recalling firm

Firm
Cardinal Health Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
7000 Cardinal Pl, N/A, Dublin, Ohio 43017-1091

Distribution

Quantity
3 units
Distribution pattern
Nationwide Within the U.S.

Timeline

Recall initiated
2025-07-30
FDA classified
2025-08-07
Posted by FDA
2025-08-13
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0573-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: drug · FDA Drug Recalls